- Home
- SF vs EXAS Comparison
SF vs EXAS Comparison
Compare SF & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SF | EXAS |
|---|---|---|
| Founded | 1890 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 11.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SF | EXAS |
|---|---|---|
| Price | $121.26 | $101.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 20 |
| Target Price | ★ $126.88 | $76.38 |
| AVG Volume (30 Days) | 705.3K | ★ 9.7M |
| Earning Date | 10-22-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 2.14 | N/A |
| EPS | ★ 5.66 | N/A |
| Revenue | ★ $5,293,276,000.00 | $3,082,033,000.00 |
| Revenue This Year | $13.37 | $16.68 |
| Revenue Next Year | $11.33 | $12.36 |
| P/E Ratio | $21.57 | ★ N/A |
| Revenue Growth | 11.76 | ★ 14.47 |
| 52 Week Low | $73.27 | $38.81 |
| 52 Week High | $125.73 | $101.87 |
Technical Indicators
Market Signals| Indicator | SF | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 90.52 |
| Support Level | $118.82 | $101.01 |
| Resistance Level | $122.52 | $101.61 |
| Average True Range (ATR) | 3.31 | 2.63 |
| MACD | 0.00 | 1.94 |
| Stochastic Oscillator | 62.45 | 98.21 |
Price Performance
Historical ComparisonAbout SF Stifel Financial Corporation
Stifel Financial Corp is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its world-wide wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.